4694
BML, INC.
株式会社ビー・エム・エルBML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
Price
¥3,485
Market Cap
¥135.9B
Ent. Value
—
Net Cash
est
—
Shares Out.
39.0M
P / E
21.7×
EV / EBIT
—
P / Book
1.05×
P / NCAV
2.32×
Div. Yield
3.44%
Financials
| Metric |
FY 2024
EDINET ↗ |
FY 2023
EDINET ↗ |
FY 2022
EDINET ↗ |
FY 2021
EDINET ↗ |
|---|---|---|---|---|
| Net Sales | ¥143.2B | ¥138.0B | ¥159.5B | ¥186.1B |
| Cost of Sales | ¥97.3B | ¥92.3B | ¥98.0B | ¥99.1B |
| Gross Profit | ¥45.9B | ¥45.6B | ¥61.4B | ¥87.0B |
| SG&A | ¥36.5B | ¥36.5B | ¥37.5B | ¥38.1B |
| Operating Income | ¥9.4B | ¥9.2B | ¥23.9B | ¥48.9B |
| Non-Operating Income | ¥776M | ¥651M | ¥500M | ¥2.3B |
| Dividend Income | ¥290M | ¥229M | — | — |
| Non-Operating Expenses | ¥170M | ¥213M | ¥254M | ¥104M |
| Interest Expense | ¥118M | ¥104M | ¥40M | ¥36M |
| Ordinary Income | ¥10.0B | ¥9.6B | ¥24.2B | ¥51.1B |
| Pre-tax Income | ¥9.7B | ¥9.5B | ¥24.2B | ¥50.3B |
| Income Taxes | ¥3.2B | ¥3.3B | ¥8.0B | ¥15.7B |
| Current Tax | ¥3.2B | ¥3.2B | ¥7.2B | ¥15.8B |
| Deferred Tax | ¥-23M | ¥41M | ¥846M | ¥-195M |
| Net Income (owners) | ¥6.3B | ¥6.0B | ¥15.6B | ¥33.7B |
| Minority Interest | ¥245M | ¥228M | ¥578M | ¥937M |
| Comprehensive Income | ¥7.2B | ¥7.6B | ¥15.4B | ¥34.7B |
| EBITDA | ¥17.1B | ¥16.0B | ¥30.3B | ¥54.8B |
| Goodwill Amort. (J-GAAP) | — | ¥91M | ¥91M | ¥91M |
| EPS | ¥160.62 | ¥154.81 | ¥395.84 | ¥833.24 |
| Shares Outstanding | 39.0M | 39.0M | 39.0M | 39.9M |
| Shares Issued (total) | 42.3M | 42.3M | 42.6M | 43.5M |
| Treasury Shares | 3.3M | 3.3M | 3.6M | 3.6M |